All In Biotech

Drug Trial Radar · NCT04317248

"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma

Precision Study on "Cocktail" Therapy to Improve the Efficacy of Hepatitis B-related Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

600

Planned (sponsor's estimate)

Start

Apr 1, 2020

Primary completion

Apr 30, 2022

Study completion Apr 30, 2022

Sponsor

Lead sponsor
Yuehua HuangAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sun Yat-sen University; Nanfang Hospital, Southern Medical University
First posted
Mar 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer cells escaping from immune surveillance and constructs an immunosuppressive microenvironment. Correspondingly, multiple signals loaded dendritic cells vaccine can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Therefore, we put forward a new scientific therapy called "multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide" combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma to prolong their survival time.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • CyclophosphamideDrug

    Intravenous drip,250mg/m\^2 per time,two days before each times of MSDCV therapy,total 6 times, in order to improve the immunosuppressive microenvironment of tumor,reduce CD4+CD25+FOXP3+regulatory T cells (Tregs)

  • Multiple Signals loaded Dendritic Cells VaccineBiological

    one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free-Survival (PFS), monthTime frame: 240 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer center

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The Third Affiliated Hospital of Zhongshan University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.